CytoImmune Therapeutics Hosting Key Opinion Leader Webinar on Human Natural Killer (NK) Cell Immunotherapy

MONROVIA, Calif.: MONROVIA, Calif., July 19, 2021 /PRNewswire/ -- CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of NK cell-based therapies for cancer, announced today that it will host a key opinion webinar (KOL) on human natural killer (NK) cell immunotherapy on Monday, July 26 at 10 am...

Click to view original post